Study identifier:D1950C00013
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 in Young and Elderly Healthy Japanese volunteers after oral Single and Repeated Doses
Healthy
Phase 1
Yes
AZD1446, Placebo
All
24
Interventional
20 Years - 80 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD1446 in young and elderly healthy Japanese volunteers.
Location
Location
Fukuoka, Fukuoka, Japan
Arms | Assigned Interventions |
---|---|
Experimental: 1 Oral capsule. Dose single and followed by 5-day repeated dosing. Specific doses depend on panel. | Drug: AZD1446 oral capsule, Moderate Release |
Placebo Comparator: 2 Oral capsule. Dose single and followed by 5-day repeated dosing. | Drug: Placebo oral capsule Other Name: Placebo |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.